FDA News: FDA approves new treatments for heart disease caused by a rare disease, transthyretin mediated amyloidosis

11May - by Editor - 0 - In STL.News

Silver Spring, MD (STL.News) – On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults.  These are the first FDA-approved treatments for ATTR-CM.  Vyndaqel and Vyndamax have the same active moiety, tafamidis, but they are not substitutable on a milligram to milligram basis and their recommended doses differ. “Transthyretin-mediated amyloidosis is a rare, debilitating and often fatal disease,” said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Drugs in the FDA’s Center for Drug Evaluation and Research. 

Continue reading FDA News: FDA approves new treatments for heart disease caused by a rare disease, transthyretin mediated amyloidosis at STL.News.

Source link